Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 3/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291867 | 0.87 | MMP13 (0.65) | MMP13CYP19A1TBXAS1KDM4EALDH1A1 | |
| SCHEMBL5697180 | 0.86 | MMP13 (0.60) | MMP13CYP19A1TBXAS1NPC1POLB | |
| SCHEMBL6287173 | 0.85 | TET2 (0.35) | MMP13CYP19A1 | |
| SCHEMBL6286878 | 0.82 | MMP13 (0.50) | MMP13 | |
| SCHEMBL6818379 | 0.80 | MMP13 (0.40) | MMP13 | |
| SCHEMBL6246431 | 0.78 | MMP13 (0.62) | MMP13CYP19A1 | |
| SCHEMBL6291887 | 0.74 | MAPK10 (0.39) | ALDH1A1 | |
| SCHEMBL6180033 | 0.73 | MMP13 (0.44) | MMP13CYP19A1 | |
| SCHEMBL6288426 | 0.73 | TET2 (0.37) | MMP13 | |
| SCHEMBL6177228 | 0.72 | MMP13 (0.43) | MMP13CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | claimed |
| US-6974822-B2 | 3-isoquinolinone derivatives as matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2005-12-13 | — | — | US | disclosed |
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | BUNKER AMY MAE (US) | 2004-02-26 | — | — | US | disclosed |
| WO-2004014378-A1 | 3-ISOQUINOLINONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038959-A1 | 3-Isoquinolinone derivatives as matrix metalloproteinase inhibitors | MMP1, MMP9, MMP3 | MMP13 5/4885CYP19A1 1152/4885TBXAS1 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.